Available | Phase III
Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane (CONTESSA)
To compare and assess the efficacy, safety and tolerability of Tesetaxel plus a reduced dose of Capecitabine alone with HER2 negative, HR positive, LA/MBC previously treated with a Taxane in the neoadjuvant or adjuvant setting.
Group 1: Tesetaxel and Capecitabine
Group 2: Capecitabine
Key Participation Requirements:
Male or Female
19 years and older
HER2 negative, HR positive
Measureable disease or bone-only disease
Prior therapy with taxane
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.
To learn more about this clinical trial please contact us today!